about
Linkers Having a Crucial Role in Antibody-Drug ConjugatesProgress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery SystemsSubstrate mediated enzyme prodrug therapyPEG-pHPMAm-based polymeric micelles loaded with doxorubicin-prodrugs in combination antitumor therapy with oncolytic vaccinia viruses.Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.Glucuronides from metabolites to medicines: a survey of the in vivo generation, chemical synthesis and properties of glucuronides.Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.Metabolic disposition and biological significance of simple phenols of dietary origin: hydroxytyrosol and tyrosol.Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.Expanded Utility of the β-Glucuronide Linker: ADCs That Deliver Phenolic Cytotoxic Agents.A heterodimeric glucuronide prodrug for cancer tritherapy: the double role of the chemical amplifier.A modified Tat peptide for selective intracellular delivery of macromolecules.Targeting the tumour microenvironment with an enzyme-responsive drug delivery system for the efficient therapy of breast and pancreatic cancers.Orally administered isoflavones are present as glucuronides in the human prostate.Isogloiosiphone B, a novel acetal, and hydrophobic compounds as β-glucuronidase inhibitors derived from the red alga Neodilsea yendoana.Diamagnetic Imaging Agents with a Modular Chemical Design for Quantitative Detection of β-Galactosidase and β-Glucuronidase Activities with CatalyCEST MRI.Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications.Enzyme-Activated Fluorogenic Probes for Live-Cell and in Vivo Imaging
P2860
Q26752763-A821D452-CE5F-4EA6-9DEB-EDEA4797644CQ26782485-3584276F-3010-4A2B-B20E-B586E99D493FQ28485159-550788C2-6A5D-4BF0-B2D3-828EEBD61AB4Q34403672-9A147F99-5333-47BF-8335-ECB95A7E743AQ35459059-7E27902B-A214-4373-BCDE-B2779DBFDD97Q38104574-570D1475-7D29-4117-A1F1-8109E1CF8544Q38177279-5248BE4A-4FA6-473E-8E86-E9507BDB70CAQ38836138-ACDD0E53-5DBD-4EF2-A627-99E938EC0A6FQ38979784-02621B45-1BC6-44BF-9A3F-63EBD1C588ABQ39157615-A36278B0-07A6-48B3-BAD4-0C85C483D6B1Q39495340-6D4D0AC5-A904-480E-94D1-E95A64EBBD19Q39558788-ADFF39FB-4497-46AC-BAC2-029ED7E9DEB8Q41986758-865A5323-94F3-4A34-A258-502B14C4CC51Q46515450-1E29B0F7-2D89-4BF1-9C91-E7B94FE5398BQ50061944-DA032615-2949-4BFB-9060-B2ECD4A1B42AQ51156646-11324E49-CEC5-45B2-97F8-9948525939BDQ52593621-0AB14F42-D84B-48EB-A91A-CA7C04E28F2FQ57175185-25C458C5-0057-4765-9A47-389DB148D606
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Beta-glucuronidase-mediated drug release.
@ast
Beta-glucuronidase-mediated drug release.
@en
Beta-glucuronidase-mediated drug release.
@nl
type
label
Beta-glucuronidase-mediated drug release.
@ast
Beta-glucuronidase-mediated drug release.
@en
Beta-glucuronidase-mediated drug release.
@nl
prefLabel
Beta-glucuronidase-mediated drug release.
@ast
Beta-glucuronidase-mediated drug release.
@en
Beta-glucuronidase-mediated drug release.
@nl
P2093
P356
P1476
Beta-glucuronidase-mediated drug release.
@en
P2093
Epie Boven
Hans W Scheeren
Herbert M Pinedo
Hidde J Haisma
Michelle de Graaf
P304
P356
10.2174/1381612023394485
P577
2002-01-01T00:00:00Z